Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
Hypersensitivities01:30

Hypersensitivities

Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Allergic Reactions: Anaphylaxis01:30

Allergic Reactions: Anaphylaxis

Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin, heparin),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Using feeding regime as a microbial selective pressure to optimise biogas production and digestate sanitisation from slurry-based anaerobic digestion.

Environmental microbiome·2026
Same author

Correspondence: The First Biosimilar for Biologics in Allergy: CT-P39 (Omlyclo-Omalizumab-Igec) Is Available for Asthma, Chronic Spontaneous Urticaria, and Chronic Rhinosinusitis With Nasal Polyps.

Allergy·2026
Same author

[Use of Omalizumab-biosimilars for CRSwNP in the German Health Care System - a Position Paper of the German Societies for Allergy AeDA and ORL DGHNO-KHC].

Laryngo- rhino- otologie·2026
Same author

Correspondence: First Peanut (Arachis hypogaea) Allergen Oral Immunotherapy Product Out of Sale-A Major Drawback for Food Allergy Immunotherapy?

Allergy·2026
Same author

[Different immunological types of CRSwNP in the context of the new European EAACI nomenclature : Part 3: Hypersensitivity reactions of type VI].

HNO·2026
Same author

The Unmet Need of Olfactory Testing in Inflammatory Disorders of the Upper Airways-An EAACI Position Paper.

Allergy·2026
Same journal

[The digits-in-noise test in audiological cochlear implant aftercare].

HNO·2026
Same journal

[Complications of acute otitis media].

HNO·2026
Same journal

HNO·2026
Same journal

[Facial fillers: evidence base, anatomical principles, materials, risks, techniques, and future perspectives].

HNO·2026
Same journal

Prevention in otology-the key to lifelong hearing health.

HNO·2026
Same journal

[Bilateral low-frequency hearing loss and tinnitus following spinal anesthesia during a cesarean section].

HNO·2026
See all related articles

Related Experiment Video

Updated: Jun 17, 2026

Murine Model of Epicutaneously-Induced Immunomodulation
09:07

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

[Specific immunotherapy with depigmented allergoids].

L Klimek1, C Thorn, O Pfaar

  • 1Zentrum für Rhinologie und Allergologie, An den Quellen 10, 65183, Wiesbaden, Deutschland. Ludger.Klimek@Allergiezentrum.org

HNO
|December 17, 2009
PubMed
Summary
This summary is machine-generated.

Specific immunotherapy using modified polymerized allergoids offers a safer and effective treatment for IgE-mediated allergies. This novel approach allows for rapid administration, improving patient tolerance and reducing adverse effects.

More Related Videos

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Related Experiment Videos

Last Updated: Jun 17, 2026

Murine Model of Epicutaneously-Induced Immunomodulation
09:07

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Area of Science:

  • Immunology
  • Allergy Treatment
  • Pharmacology

Background:

  • Specific immunotherapy is the primary causative treatment for IgE-mediated allergic conditions.
  • Current methods include subcutaneous injections with crude extracts, semidepot extracts, or allergoids.

Purpose of the Study:

  • To evaluate a novel purification method for specific immunotherapy agents.
  • To assess the safety and efficacy of depigmented and polymerized allergoids.

Main Methods:

  • A new purification technique involving depigmentation and glutaraldehyde polymerization was employed.
  • Clinical trials were conducted to assess tolerance and adverse effects.
  • Effectiveness was compared to traditional crude allergen extracts.

Main Results:

  • Modified polymerized allergoids demonstrated increased tolerance and reduced local/systemic adverse effects.
  • Effectiveness was found to be comparable to standard specific immunotherapy.
  • Safe rush titration, including ultra-rush (1-day) protocols, is feasible with these modified allergoids.

Conclusions:

  • Depigmentation and polymerization represent a promising advancement in specific immunotherapy.
  • This modified approach enhances patient safety and tolerability.
  • Rapid administration protocols are viable, potentially improving treatment accessibility.